A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis

← catalyst calendar

NCT06815380 · readout ≤ 955 d

Sponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

1,000estimated

Sites

Country

Denmark

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-01-23

actual

When the study began enrolling

Primary completion

Mar 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2029

estimated

The whole study's end, after follow-up

First posted

2025-02-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-02-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Atopic Dermatitis
Eczema

Intervention

Other: No Intervention

Primary outcomes

what the primary-completion date above is the date OF

Absolute Measures in the Overall Health-related Well-being Index Evaluated Through World Health Organization (WHO-5) Score Throughout the Study Observation Period

measured Baseline up to Week 104

Change From Baseline in the Overall Health-related Well-being Index Evaluated Through WHO-5 Score Throughout the Study Observation Period

measured Baseline up to Week 104

Publications

PMID 40645621 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed